Avenue Therapeutics to Join Maxim Group's 2024 Healthcare Summit
Avenue Therapeutics, Inc. (NASDAQ: ATXI), a renowned specialty pharmaceutical company dedicated to addressing neurologic diseases, is set to partake in an engaging fireside chat during Maxim Group's 2024 Healthcare Virtual Summit. Alexandra MacLean, the company's Chief Executive Officer, will lead the discussion, scheduled for October 15. This opportunity highlights the Company's commitment to its mission and brings insights to investors and healthcare professionals alike.
Fireside Chat Details and Investment Opportunities
The fireside chat at the summit, accessible only to registered attendees, will be a platform for discussing Avenue Therapeutics' innovative approach and therapeutic developments. Investors interested in participating in this insightful event can register through the summit's official platform. The interaction will provide valuable information and allow attendees to ask pertinent questions directly, enhancing engagement with the company's vision and projects.
Focus on Neurologic Diseases
Avenue Therapeutics is on a mission to pioneer treatments aimed at neurologic diseases. By exploring various assets, including AJ201, they strive to offer solutions for conditions like spinal and bulbar muscular atrophy. This dedication underlines their commitment to overcoming the challenges faced by individuals suffering from these nuanced conditions.
Innovative Therapies in Development
The Company is currently advancing three significant therapeutic assets. AJ201 stands out as a first-in-class treatment designed specifically for spinal and bulbar muscular atrophy. Additionally, BAER-101 is an orally administered selective GABAA ?2, ?3 receptor positive allosteric modulator, demonstrating promise in the treatment of various central nervous system disorders. Moreover, Avenue is developing IV tramadol, a therapy targeted at managing acute postoperative pain in adults, which will be implemented in medically supervised healthcare environments.
Background Information on Avenue Therapeutics
Avenue Therapeutics, Inc., based in Miami, Florida, was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). Their ongoing dedication and innovative spirit drive their success in the pharmaceutical industry. As the company continues to expand its portfolio and enhance its research capabilities, its established reputation for tackling neurologic diseases positions it as an essential player in the pharmaceutical landscape.
Opportunities for Investors and the Future
For potential investors, Avenue Therapeutics represents an opportunity to engage with a company heavily focused on addressing critical health issues through innovative therapies. As the landscape of neurologic disease treatment evolves, Avenue's commitment to research and development will continue to draw attention from investors eager to support transformative health solutions.
Frequently Asked Questions
What is Avenue Therapeutics focused on developing?
Avenue Therapeutics focuses on therapies for neurologic diseases, with three main assets in development.
When is the fireside chat scheduled?
The fireside chat is scheduled for October 15 during Maxim Group's 2024 Healthcare Virtual Summit.
Who will be speaking at the event?
Alexandra MacLean, M.D., the CEO of Avenue Therapeutics, will participate in the fireside chat.
What is BAER-101?
BAER-101 is an oral small molecule that acts as a selective GABAA ?2, ?3 receptor positive allosteric modulator designed for central nervous system diseases.
How can investors participate in the event?
Investors can register for the event through the summit’s official platform to gain access.
